{
    "info": {
        "nct_id": "NCT05118789",
        "official_title": "A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)",
        "inclusion_criteria": "1. Age ≥18 years (Cohort 2e only: Age ≥12 years and weighing>40 kg).\n2. Disease Criteria:\n\n   1. Phase 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with documented ROS1 rearrangement.\n   2. Phase 2: Cohorts 2a, 2b, 2c and 2d: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with ROS1 rearrangement.\n   3. Phase 2: Cohort 2e: Histologically or cytologically confirmed locally advanced or metastatic solid tumor (other than NSCLC) with ROS1 rearrangement.\n3. Prior anticancer treatment (except cohort 2a).\n4. Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1. Phase 2: Must have measurable disease according to RECIST 1.1.\n5. Adequate baseline organ function and bone marrow reserve.\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
        "exclusion_criteria": "1. Patient's cancer has a known oncogenic driver alteration other than ROS1.\n2. Known allergy/hypersensitivity to excipients of NVL-520.\n3. Major surgery within 4 weeks of first dose of study drug.\n4. Ongoing anticancer therapy.\n5. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "3. Prior anticancer treatment (except cohort 2a).",
            "criterions": [
                {
                    "exact_snippets": "Prior anticancer treatment (except cohort 2a)",
                    "criterion": "prior anticancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Adequate baseline organ function and bone marrow reserve.",
            "criterions": [
                {
                    "exact_snippets": "Adequate baseline organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "baseline",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... bone marrow reserve",
                    "criterion": "bone marrow reserve",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1. Phase 2: Must have measurable disease according to RECIST 1.1.",
            "criterions": [
                {
                    "exact_snippets": "Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1.",
                    "criterion": "disease status (Phase 1)",
                    "requirements": [
                        {
                            "requirement_type": "evaluable disease (target or nontarget) according to RECIST 1.1",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Phase 2: Must have measurable disease according to RECIST 1.1.",
                    "criterion": "disease status (Phase 2)",
                    "requirements": [
                        {
                            "requirement_type": "measurable disease according to RECIST 1.1",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Phase 2: Cohort 2e: Histologically or cytologically confirmed locally advanced or metastatic solid tumor (other than NSCLC) with ROS1 rearrangement.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed",
                    "criterion": "tumor diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic solid tumor",
                    "criterion": "tumor stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "tumor type",
                            "expected_value": "solid tumor"
                        }
                    ]
                },
                {
                    "exact_snippets": "(other than NSCLC)",
                    "criterion": "tumor type exclusion",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "NSCLC"
                        }
                    ]
                },
                {
                    "exact_snippets": "with ROS1 rearrangement",
                    "criterion": "ROS1 rearrangement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Phase 2: Cohorts 2a, 2b, 2c and 2d: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with ROS1 rearrangement.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed",
                    "criterion": "NSCLC diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic NSCLC",
                    "criterion": "NSCLC stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "NSCLC with ROS1 rearrangement",
                    "criterion": "ROS1 rearrangement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Disease Criteria:",
            "criterions": [
                {
                    "exact_snippets": "Disease Criteria",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "criteria related to disease (details not specified in this line)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Age ≥18 years (Cohort 2e only: Age ≥12 years and weighing>40 kg).",
            "criterions": [
                {
                    "exact_snippets": "Age ≥18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Cohort 2e only: Age ≥12 years and weighing>40 kg",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Cohort 2e only: Age ≥12 years and weighing>40 kg",
                    "criterion": "body weight",
                    "requirements": [
                        {
                            "requirement_type": "minimum weight",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 12 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 12 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Phase 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with documented ROS1 rearrangement.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed",
                    "criterion": "solid tumor diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic solid tumor",
                    "criterion": "tumor stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "solid tumor with documented ROS1 rearrangement",
                    "criterion": "ROS1 rearrangement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "2. Known allergy/hypersensitivity to excipients of NVL-520.",
            "criterions": [
                {
                    "exact_snippets": "Known allergy/hypersensitivity to excipients of NVL-520",
                    "criterion": "allergy or hypersensitivity to excipients of NVL-520",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Ongoing anticancer therapy.",
            "criterions": [
                {
                    "exact_snippets": "Ongoing anticancer therapy",
                    "criterion": "anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Patient's cancer has a known oncogenic driver alteration other than ROS1.",
            "criterions": [
                {
                    "exact_snippets": "cancer has a known oncogenic driver alteration other than ROS1",
                    "criterion": "oncogenic driver alteration",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "other than ROS1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.",
            "criterions": [
                {
                    "exact_snippets": "Actively receiving systemic treatment",
                    "criterion": "systemic treatment",
                    "requirements": [
                        {
                            "requirement_type": "current status",
                            "expected_value": "actively receiving"
                        }
                    ]
                },
                {
                    "exact_snippets": "direct medical intervention on another therapeutic clinical study",
                    "criterion": "direct medical intervention on another therapeutic clinical study",
                    "requirements": [
                        {
                            "requirement_type": "current status",
                            "expected_value": "receiving"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Major surgery within 4 weeks of first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks of first dose of study drug.",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}